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Copper is a chemical element required for the normal functioning of many molecules involved in the signal transduction pathway regulating cell proliferation. It plays an important role in tumor angiogenesis (1) (2) (3) and can stimulate endothelial cell proliferation (4) . So far, we know that copper metabolism and its cellular deposition are altered in neoplastic disease (5) . Several authors have reported an increased copper content in tumors (6, 7) , giving rise to the possibility of using elevated copper concentration in cancer cells as an imaging biomarker for metabolic PET imaging (8, 9) . Human copper transporter 1 is a high-affinity copper transporter that mediates cellular uptake of copper in humans (10) . This transporter is well represented in human cancer, including prostate tumor cells. Preclinical studies have shown that human prostate cancer (PCa) xenograft models in mice display an increased uptake of copper administered as 64 CuCl 2 (10, 11) . So far, only one paper, involving few patients, has confirmed the ability of 64 CuCl 2 PET/CT to detect PCa sites of disease in humans (12) . To the best of our knowledge, no studies have assessed the ability of 64 CuCl 2 PET/CT to detect PCa relapse after surgery or external-beam radiation therapy (EBRT).
Whereas 18 F-choline and 11 C-choline remain the most validated tracers for the detection of recurrent PCa (13, 14) , they have significant limitations in terms of sensitivity in the case of low prostatespecific antigen (PSA) level and long PSA doubling time (15) . In this field, the recent introduction of new PET radiopharmaceuticals (e.g., 68 Ga-PSMA and 18 F-FACBC) (16) (17) (18) (19) , and the possibility of obtaining PET/MRI using dedicated software (20, 21) or dedicated tomographs (22) , have increased sensitivity in the early detection of PCa relapse, especially in the case of low PSA levels.
In the current trial we aimed to evaluate, for the first time, the ability of 64 CuCl 2 PET/CT to detect PCa recurrence in patients presenting with biochemical relapse. We compared all the abovementioned results with those of 18 F-choline PET/CT and multiparametric MRI (mpMRI). We also aimed to assess the clinical safety, biodistribution, and radiation dosimetry of 64 CuCl 2 in humans. Moreover, we studied the 64 CuCl 2 kinetics of sites of PCa relapse.
MATERIALS AND METHODS
The local ethics committee and the "Agenzia Italiana del Farmaco," a public agency of the Italian Ministry of Health, approved this study. All subjects signed a written informed consent form. The trial was registered in the European Clinical Trial Database (EudraCT number 2014-005140-18).
Patient Population
From February to October 2016, we prospectively evaluated 50 PCa patients presenting with biochemical relapse (23) after first-line surgery or EBRT. We also included patients with rising PSA levels after salvage EBRT or hormone therapy. All patients underwent 64 CuCl 2 PET/CT, 18 F-choline PET/CT, and mpMRI within 15 d of one another. Table 1 shows the main characteristics of patients and tumors.
CuCl 2 PET/CT
The production of the experimental 64 CuCl 2 (Sparkle s.r.l.) was approved by Agenzia Italiana del Farmaco. The radiopharmaceutical was prepared in accordance with good manufacturing practices and administered intravenously to fasting patients ($6 h). Whole-body 64 CuCl 2 PET/CT was performed 60 min (12) after injection of 200-250 MBq of 64 CuCl 2 . PET scans were acquired in 3-dimensional mode by a PET/CT system (Discovery ST; GE Healthcare). Considering the relatively low positron production and 511-keV photon emission (yield) of 64 Cu when compared with those of 18 F, PET/CT scans were acquired via 6-min emissions per bed position from the upper neck to the upper thighs, by means of sequential fields of view, each covering 12 cm (matrix of 256 · 256). Images were visualized on a Xeleris Workstation, version 2.1753 (GE Healthcare). Low-dose CT was performed for both attenuation correction and topographic localization. The CT parameters used for acquisition were 140 kV, 80 mA, and 0.5 s per rotation, with a pitch of 6:1 and a slice thickness of 3.25 mm.
To evaluate the biodistribution and dosimetry of this radiopharmaceutical, all 50 patients underwent another 2 PET/CT acquisitions 4 h and 24 h after tracer injection. The second acquisition time (4 h) was selected in order to have a late acquisition on the same day as the tracer injection to facilitate patient compliance. The third acquisition time (24 h) was selected in order to have a late PET/CT acquisition (after 2 half-lives of the tracer) to improve the quality of the kinetics study. To evaluate the potential hepatic radiotoxicity of 64 CuCl 2 administration, according to Agenzia Italiana del Farmaco suggestions, blood tests were performed on all patients and used to determine the following parameters: hematocrit, hemoglobin, C-reactive protein, aspartate transaminase, alanine transaminase, alkaline phosphatase, albumin, total bilirubin, g-glutamyl transferase, lactate dehydrogenase, total proteins, serum creatinine, and azotemia. The tests were performed immediately before radiopharmaceutical administration and 10 d after the first 64 CuCl 2 whole-body scan.
F-Choline PET/CT
18 F-choline PET/CT was performed in the fasting state ($6 h). An 18 F-choline activity of 200 MBq (IASOcholine; IASON Labormedizin GesmbH und Co. KG) was administered intravenously; data were acquired 20 min after the injection by means of the abovementioned PET/CT system. PET was performed over an acquisition time of 3 min in the same manner as for 64 CuCl 2 PET/CT and visualized on the same workstation. The same CT parameters were also used. All patients underwent mpMRI performed with a 1.5-T MRI scanner (Signa HDxt; GE Healthcare) equipped with an 8-channel pelvic phased-array surface coil. The procedure was performed according to a standardized protocol (20) . A large-field-of-view fast spin echo T2-weighted sequence was set in order to visualize the pelvis and infrarenal paracaval and paraaortic lymph node stations. High-resolution oblique axial and coronal scans were further oriented perpendicular and parallel to the rectoprostatic plane. Diffusion-weighted imaging was acquired in the axial plane, using the same slice locations as for the first fast spin echo T2-weighted sequence. Dynamic contrast-enhanced MRI was acquired during intravenous injection of the paramagnetic contrast medium with a flow rate of 3 mL/s. A 3-dimensional spoiled gradient echo fat-saturated T1-weighted pulse sequence was repeated in the axial plane 27 times with a temporal resolution of 12 s, during the injection of a single dose of contrast agent. An axial short T1 inversion recovery sequence was performed to detect focal bone lesions.
Image Interpretation
All PET images were reviewed by 2 experienced nuclear medicine physicians (at least 5 y of experience in PET/CT examinations) masked to other PET/CT and mpMRI results. On 18 F-choline PET/CT and 64 CuCl 2 PET/CT, any focal, nonphysiologic uptake higher than that of the surrounding background level was considered pathologic. The reference tissues were the prostate parenchyma, prostatic fossa, residual seminal vesicles, vesicourethral anastomoses, abdominal and pelvic lymph nodes, and bone. 18 F-choline PET/CT and 64 CuCl 2 PET/CT studies were interpreted visually and semiquantitatively using the SUV max , on a patient-bypatient and lesion-by-lesion basis. In patient-based analysis, detection rate (DR) was defined as the ability to detect at least one pathologic finding in each subject. In lesion-based analysis, the DR was defined as the ability to detect suspected lesions in relation to the total number of lesions detected by both tracers and mpMRI (17) .
Tumor-to-background ratios (TBRs) were determined for each lesion on both the 64 CuCl 2 and the 18 F-choline images. TBR was established by placing a 2-dimensional region of interest in the pelvis and measuring the SUV max of the background fat within the area (16) . This value was then used as the denominator for the TBR. No SUV max or TBR cutoffs were introduced to assess tumor lesions, although these parameters were calculated as a support to visual interpretation.
All mpMRI studies were reviewed on a dedicated workstation (Advantage Workstation, version 4.6; GE Healthcare) by an abdominal radiologist (with at least 5 y of experience in prostate mpMRI) masked to the results of the PET studies.
PCa recurrence was diagnosed when a focal morphologic alteration was accompanied by at least one corresponding functional abnormality (on apparent-diffusion-coefficient or perfusion maps) or when 2 functional mpMRI criteria were present without a definite morphologic lesion. Morphologic criteria were also adopted to distinguish between benign and malignant lymph nodes (i.e., short-axis diameter . 10 mm) (20, 21) . The axial short T1 inversion recovery sequence was used to detect bone metastases.
Standard of Reference
Although only DRs were calculated for each diagnostic modality, we applied a standard of reference, which could provide some confirmation of the site of disease. Histopathology was performed on transrectal ultrasound-guided biopsy in 7 of 25 patients (28%) showing only local recurrence; this confirmed the presence of disease. Moreover, undetectable PSA values were found after salvage EBRT in another 4 of the 11 patients with only local recurrence and not previously treated with EBRT. For lymph node and distant metastases, we used a multidisciplinary follow-up based on mpMRI, 18 F-choline PET/CT, and reduction of PSA values after salvage therapy. A median follow-up time of 7 mo (range, 5-15 mo) was available for each patient.
Radiation Dosimetry
For dosimetric calculation, volumes of interest were drawn, for all PET and CT datasets, using automatic rigid coregistration (PMOD). Time-activity curves for all organs and for the total body were fitted as a biexponential function. We calculated accumulated activity for each organ (the sum of all nuclear transitions inside the organ) as the area under the time-activity curve, and the residence time was obtained by dividing accumulated activity by administered activity. The accumulated activity of the remainder of the body was calculated by subtracting all source organs from the total-body activity. The absorbed dose for each organ was calculated using the MIRD system (24, 25) . S factors specific for a reference adult male for 64 Cu are tabulated in OLINDA/EXM software (26) . The effective dose was also calculated using the coefficients of radiosensitivity of the organs present in publications 60 and 103 of ICRP (27, 28) .
Lesion Kinetics
To evaluate lesion kinetics, volumes of interest were drawn for all PET and CT datasets using automatic rigid coregistration (PMOD). Time-activity curves for various lesions (all local-relapse lymph-node metastases with short axis diameter . 15 mm and all bones metastases) were fitted as a biexponential function to calculate maximum specific uptake and clearance.
Statistical Methods
Since no literature data were available on the experimental diagnostic method used, no formal test hypothesis or sample size calculation was made; therefore, the study was intended as a pilot, and sample size (n 5 50) was determined on the basis of feasibility. The primary objective was to calculate and compare the DRs of the experimental tests ( 64 CuCl 2 PET/CT) with those of the standard tests ( 18 F-choline PET/CT and mpMRI).
The main descriptive statistics used were median, minimum, and maximum for continuous data and absolute and relative frequency for categoric data. DRs were calculated as the ratio between the number of positive patients (or lesions in the case of lesion-based analysis) and the total number of patients enrolled (or lesions). The exact binomial 95% confidence intervals of the DRs were calculated. The x 2 and Fisher exact tests were adopted to compare categoric data; the exact McNemar test was used to compare DRs between diagnostic procedures on the same subjects, also stratified by total PSA levels (,1, 1.1-2, 2.1-4, and .4 ng/mL). A 2-tailed, paired test was used to analyze and compare TBR ratios between scans. Because the study was exploratory, no corrections for multiple tests were applied. Statistical significance was assigned to values of a-error (2-tailed) lower than 0.05. All statistical analyses used Stata software (release 14; StataCorp LP).
RESULTS

Adverse Events
No drug-related pharmacologic effects or physiologic responses occurred. No adverse reactions were observed after the injection of 64 CuCl 2 . All observed parameters (i.e., blood pressure, heart rate, body temperature) remained normal and unchanged during and after the examination. No patient reported subjective symptoms. In addition, no modification of the above-mentioned blood tests was reported 10 d after 64 CuCl 2 injection.
Tracer Distribution and Dosimetry
Physiologic uptake of 64 CuCl 2 differed from that of 18 F-choline. 64 CuCl showed high uptake in the liver and less intense uptake in the salivary glands, biliary tract, pancreas, spleen, and kidney. No significant 64 CuCl uptake was found in the bone marrow. 64 CuCl was not excreted via the urinary tract, and no accumulation in the bladder was found (Fig. 1) .
The critical organ for 64 CuCl is the liver, as was already reported in ICRP 53 (29) and in a study by Capasso et al. (12) . The liver accumulates about 30% of the administered activity, and the absorbed dose is 2.71E21 mGy/MBq. Table 2 shows the absorbed dose per administered activity and comparison with 18 F-choline and 68 Ga-PSMA. Uptake in the liver, pancreas, and gallbladder maximizes about 1.5-2 h after administration, whereas the kidneys, spleen, and salivary glands have rapid uptake, maximizing in less than 1 h. Supplemental Figure 1 (supplemental materials are available at http:// jnm.snmjournals.org) shows typical time-activity curves (as percentages of the injected activity) for the various source organs. Radiation dosimetry revealed an effective dose of 2.83E22 mSv/MBq.
Lesion Kinetics
As in the case of organs at risk, time-activity curves for lesions showed rapid uptake, maximizing about 1 h after administration (Supplemental Fig. 2 ). The study of the lesion time-activity curves revealed a slow clearance dictated by the radionuclide physical halflife (mean effective half-life, 9.5 h). 
Patient-Based Analysis
PCa relapse was found in 44 patients. Local relapse was detected in 34 patients (68%). We identified lymph node metastases in 17 patients (34%) and bone metastases in 5 patients (10%). Table 3 summarizes the differences in DR between 64 CuCl 2 PET/CT and each of the other 4 diagnostic modalities and shows the DRs recorded when different sites of PCa recurrence were considered separately. The difference between the DR of 64 CuCl 2 PET/CT and that of 18 F-choline PET/CT was statistically significant (P 5 0.002).
When the level of PSA was considered (Fig. 2) , 64 CuCl 2 PET/ CT identified a higher number of positive patients than did 18 Fcholine PET/CT in every PSA level cohort, except for a PSA level of more than 4 ng/mL.
When we considered the differences between the prostatectomy and nonprostatectomy populations, we found that 64 CuCl 2 PET/ CT identified a higher number of positive patients than did 18 Fcholine PET/CT among those treated with surgery (P 5 0.001). In particular, 64 CuCl 2 PET/CT identified a significantly higher number (P , 0.001) of local relapses (Supplemental Table 1 ).
A detailed description of the multidisciplinary standard of reference considered for each patient is provided in Supplemental Figure 3 .
Lesion-Based Analysis
To determine the DR of each modality in detecting recurrent lesions in different anatomic locations, we also performed a lesion-based analysis; the results are summarized in Table 4 . Overall, 118 lesions were detected in our analysis, 44 of which were local relapses, 60 abdominal lymphnode metastases, and 14 bone metastases (pelvis, proximal femurs, and lumbar spine). Indeed, 64 CuCl 2 PET/CT showed significantly higher DRs than did 18 Fcholine PET/CT and mpMRI (Table 4) . The DR of 64 CuCl 2 PET/CT was particularly high in the case of local relapse. Two cases of local recurrence are illustrated in Figures 3 and 4 . In addition, 64 CuCl 2 PET/CT identified a significantly higher number of lymph node metastases than did 18 F-choline PET/CT and mpMRI. In particular, all lymph nodes with positive 64 CuCl 2 and negative 18 F-choline findings had a short-axis diameter of less than 7 mm. Two cases are illustrated in Figures 5 and 6 . In the event of bone metastases, mpMRI showed the highest DR. No difference in bone DR was observed between 18 F-choline PET/CT and 64 CuCl 2 PET/CT (Fig. 7) .
All 18 F-choline-positive PCa lesions (local, lymph nodes, and bone) showed 64 CuCl 2 uptake.
More generally, the 64 CuCl 2 TBR evaluated 1 h after tracer injection was higher than that of 18 F-choline. The mean TBR was 13.4 for 18 F-choline and 16.4 for 64 CuCl 2 (P 5 0.02). The typical time-activity curves of 64 CuCl 2 for fat, marrow, and muscles compared with that of one site of disease is illustrated in Supplemental Figure 4 .
DISCUSSION
Our study was the first to prospectively evaluate the biodistribution, dosimetry, and lesion kinetics of 64 CuCl 2 in a considerable number of PCa patients with biochemical relapse.
We found that the biodistribution of 64 CuCl 2 was more suitable than that of 18 F-choline in evaluating PCa relapse, as 64 CuCl 2 is neither excreted nor accumulated in the urinary tract. This enables better assessment of the pelvis and prostatic fossa, thus increasing the possibility of identifying small lesions close to the bladder or vesicourethral anastomosis.
We found that the critical organ for 64 CuCl 2 was the liver, and we showed that the effective dose and liver exposure were lower than those calculated previously in only 7 patients (11% less and 8% less, respectively) (12). Our findings imply that potential hepatic radiotoxicity might be induced only by means of a high injected activity. We also found that the effective dose of 64 CuCl 2 was about 40% greater than that of 18 F-choline (30) . Thus, for an administered activity of 200 MBq, the effective dose of 64 CuCl is 5.7 mSv, whereas that of 18 F-choline is 4 mSv (30). However, this difference in radiation exposure can be considered negligible, especially in elderly patients with PCa biochemical relapse.
The time-activity curves of the PCa site of disease showed that 64 CuCl 2 has a rapid uptake that maximizes about 1 h after administration. This result supports the choice to perform PET imaging early after the injection. In addition, this analysis showed that the 64 CuCl 2 clearance in PCa relapse is slow and dictated by the radionuclide physical decay. These data on dosimetry, biodistribution, and kinetics are potentially useful. Indeed, given its decay scheme (half-life, 12.7 h; b 1 , 17.86%; b 2 , 39.0%) (31) , 64 Cu could play a dual role in the development of molecular agents for PET imaging and in oncologic therapy (32) . The additional emission of Auger electrons associated with the electron capture decay canal (electron capture, 43.075%) might considerably contribute to the possible therapeutic effectiveness of this radionuclide. Auger electrons have low kinetic energies and short-range penetration but concomitantly high linear-energy transfer (33) , like heavier particles (34, 35) . The present study might provide the basis for evaluating the radiation safety of 64 CuCl 2 and estimating the dose absorbed by organs at risk in the case of theranostic application.
Our study demonstrated that 64 CuCl 2 PET/CT could detect local recurrence and lymph node and bone metastases in PCa patients with biochemical relapse and was the first to prospectively compare the diagnostic performance of 64 CuCl 2 PET/CT with those of 18 F-choline PET/CT and mpMRI.
In our patient-based analysis, the DR of 64 CuCl 2 PET/CT was significantly higher than that of 18 F-choline PET/CT. This difference stems from the high DR of 64 CuCl 2 PET/CT in identifying local recurrence, which is often undetected by 18 F-choline PET/ CT. In this analysis, no difference emerged between 64 CuCl 2 PET/ CT and mpMRI. This is in line with the well-known high sensitivity of mpMRI in detecting local recurrence (36) .
Indeed, 64 CuCl 2 PET/CT detected more patients with PCa relapse than did 18 F-choline PET/CT in each PSA cohort, except for a PSA level of more than 4 ng/mL. These data demonstrate the high DR of 64 CuCl 2 PET/CT even in patients with a PSA level of less than 1 ng/mL. In this subgroup, more than 70% of patients presented a positive 64 CuCl 2 PET/CT, which was often consistent with local relapse. In other words, these patients may still benefit from salvage, PET-guided RT (37) .
In the lesion-based analysis, 64 CuCl 2 PET/CT had a significantly higher DR than did 18 F-choline PET/CT and mpMRI. We found that the significant difference in DR was due to the greater ability of 64 CuCl 2 PET/CT to detect both local recurrence and lymph node metastases (especially in small lymph nodes; i.e., those with a short axis diameter of ,7 mm).
These findings open a door to the possibility of using 64 CuCl 2 PET/CT in cases of suspected local PCa relapse when mpMRI remains inconclusive.
Despite our encouraging results, some important limitations should be noted. First, we assessed only the DRs of the diagnostic techniques mentioned, assuming a priori that all patients were true-positives, in that they presented with biochemical relapse. Indeed, we introduced a descriptive standard of reference, which was used only to confirm the sites of disease without providing information on the diagnostic accuracy of 64 CuCl 2 PET/CT. Second, only a few cases of local findings were confirmed histopathologically. Histopathology was performed on transrectal ultrasoundguided biopsy in 7 of 25 patients (28%) showing only local recurrence; this confirmed the presence of disease. In addition, undetectable PSA values were found after salvage EBRT in another 4 of the 11 patients with only local recurrence and not previously treated with EBRT. Generally, we found a high concordance between positive findings on 64 CuCl 2 PET/CT, 18 F-choline PET/CT, and mpMRI.
However, the lack of proper histopathologic confirmation is common in most articles (16) (17) (18) (19) 38) comparing different PET tracers in the detection of PCa recurrence. Indeed, the aim of these studies, as in our case, was not to determine the diagnostic accuracy but to assess and compare the DRs of the tracers.
CONCLUSION
The biodistribution of 64 CuCl 2 is more suitable than that of 18 Fcholine for exploring the pelvis and prostatic bed. The 64 CuCl 2 effective dose is similar to those of other established PET tracers. In patients with biochemical relapse and a low PSA level, 64 CuCl 2 PET/CT shows a significantly higher DR than does 18 F-choline PET/CT. Larger trials with this PET tracer are expected to further define its capabilities and role in the management of PCa.
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